Introduction {#sec1}
============

Adult neurogenesis is a distinctive feature of the telencephalon in the mammalian brain. Neurogenesis proceeds by neural stem cells (NSCs), giving rise to transit-amplifying cells, which subsequently differentiate into neuroblasts and mature neurons ([@bib10; @bib29; @bib31; @bib37]). Despite the presence of NSCs and the apparent constitutive neurogenesis in the subventricular zone of the lateral ventricles and in the hippocampus, the ability of mammals to replace neurons that are lost due to injury or during the course of progressive neurodegenerative diseases are modest at best ([@bib4; @bib5; @bib22]).

In contrast to mammals, several nonmammalian vertebrate species, such as teleost fishes and salamanders, display a remarkable ability to regenerate brain tissue by processes that involve extensive neurogenic events (for a recent review, see [@bib18]). Studies over the past years have substantially increased our understanding of adult neurogenesis in these species (e.g., [@bib12]). Both nongenetic and genetic cell-tracking studies revealed that cells with radial glia features act as neuronal progenitors in fishes and salamanders. These cells line the ventricular system, express GFAP, and have long processes reaching to the pial surface ([@bib8; @bib27; @bib28; @bib34]). The zebrafish telencephalon has been shown to have a distinctive heterogeneity among ventricular cells, in terms of anatomical localization and protein-expression profiles ([@bib13; @bib16; @bib30]).

Neurogenic regions have been mapped and revealed an uneven distribution of actively dividing cells with progenitor potential along the ventricular system in anamniotes ([@bib3; @bib8; @bib21]). Some of these studies indicated that a correlation between the distribution of active neurogenic niches and regions with neuroregenerative capacity exists ([@bib38]); however, the two are not necessarily linked to each other. For example, studies in the aquatic salamander *Notophthalmus viridescens* (red-spotted newt) showed extensive regeneration following ablation of neurons in regions that are essentially devoid of neurogenesis under normal conditions ([@bib8; @bib33]). Nevertheless, the newt telencephalon harbors several proliferative hot spots, such as the lateral wall of the ventricle adjacent to the dorsal pallium (Dp) and the lateral wall of the ventricle adjacent to the bed nucleus of the stria terminalis (Bst) ([@bib8]). Hence, the telencephalon is an ideal model for studying the cellular composition and regulatory mechanisms of neuronal regeneration in an environment, which is permissive for constitutive neurogenesis.

Here, we started to address to what extent GFAP^+^ ventricular cells, denoted as ependymoglia cells ([@bib33]), within and outside of the constitutively active niches are different from each other in the newt telencephalon. We define two different types of ependymoglia cells, which display uneven distribution along the ventricle. Unexpectedly, we find that the majority of ependymoglia cells display stem cell features in terms of label retention and insensitivity to treatment that eliminates rapidly dividing cells. However, these cells are not restricted to the proliferation hot spots but are dispersed along the ventricular wall and create de novo neurogenic regions after ablation of neurons. The proliferation hot spots on the other hand are largely composed of cells with characteristics of transit-amplifying populations. We also characterize dynamical changes in the cellular composition of both hot spots and non-hot spots after neuronal ablation and how Notch signaling relates to these changes.

Results {#sec2}
=======

GFAP^+^ Ependymoglia Cells Form Neurospheres {#sec2.1}
--------------------------------------------

Neurosphere formation is a hallmark of NSCs ([@bib35]). We first tested whether the newt brain harbors cells that can form neurospheres from different parts of the brain. We observed that culturing cells in media containing epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF-2) led to the formation of sphere-like structures from both the telencephalon ([Figures 1](#fig1){ref-type="fig"}A and 1B) and from dien- and mesencephalon ([Figure S1](#app2){ref-type="sec"} available online). Over 14 days, these spheres increased in size and we frequently observed large numbers of GFAP-expressing cells located in the core of the spheres ([Figure 1](#fig1){ref-type="fig"}C). Double labeling with proliferating cell nuclear antigen (PCNA) indicated that GFAP^+^ cells were proliferating ([Figure 1](#fig1){ref-type="fig"}D). Furthermore, after pulsing with the nucleotide analog, 5-ethynyl-2′-deoxyuridine (EdU), we could find EdU/GFAP double-labeled cells in the center of the spheres ([Figure 1](#fig1){ref-type="fig"}E). Upon changing to media without growth factors and allowing the spheres to attach, we found cells expressing the neuronal marker, Tuj1, and we also observed the appearance of GFAP cells in the periphery of the spheroid structures, along with cells migrating away ([Figures 1](#fig1){ref-type="fig"}F--1H). These data indicated that GFAP^+^ cells have stem cell properties.

Heterogeneity among GFAP^+^ Ependymoglia Cells {#sec2.2}
----------------------------------------------

We previously determined that proliferating ependymoglia cells are predominantly found in hot spots, which were previously defined by [@bib8] and are illustrated in [Figure 2](#fig2){ref-type="fig"}A. However, heterogeneity among ependymoglia cells was not further studied. In order to test whether we could define subpopulations among the seemingly homogenous GFAP^+^ ependymoglia cells, we performed immunohistochemical analyses using antibodies against known glial markers in combination with proliferation markers. These efforts resulted in the distinction of two subpopulations, which we subsequently denoted as type-1 and type-2 cells, respectively.

First, we looked at Sox2 and GLAST expressions, but both of these proteins were ubiquitously expressed in ependymoglia cells ([Figures 2](#fig2){ref-type="fig"}B, [S2](#app2){ref-type="sec"}A, and S2B). Next, we determined the expression pattern of glutamine synthetase (GS). We saw that GS staining clearly marked two distinct populations of ependymoglia cells. One of the populations expressed GS in addition to GFAP (type-1), whereas the other population of cells did not express GS (type-2; [Figure 2](#fig2){ref-type="fig"}C). The GS^−^ cells are found in clusters in hot spots and make up 32% ± 4% of the ependymoglia cells in hot spots ([Figures 2](#fig2){ref-type="fig"}C and [S2](#app2){ref-type="sec"}C--S2E) and most (85% ± 2%) of the proliferating ependymoglia cells in this region ([Figure 2](#fig2){ref-type="fig"}D). The remaining proliferating ependymoglia cells (15% ± 2%) in hot spots are GS^+^ type-1 cells ([Figure 2](#fig2){ref-type="fig"}D). In contrast, in non-hot spots, GS^−^ cells make up 0.3% ± 0.2% of the ependymoglia cells, whereas most (90% ± 6%) of the proliferating ependymoglia cells in the non-hot spots are GS^+^ ([Figures S2](#app2){ref-type="sec"}C--S2E, [2](#fig2){ref-type="fig"}E, and 2F). From these data, we concluded that hot spots contain both proliferating type-1 and type-2 cells, whereas non-hot spots essentially lack type-2 cells.

Given the documented role of Notch signaling in the regulation of neural stem and progenitor cell fate, we next determined the expression pattern of Notch1 receptor among the ependymoglia subpopulations defined by GS expression in hot spots and non-hot spots. We found active Notch signaling occurring in Notch1^+^ ependymoglia cells as assayed by electroporation of a reporter driven by the 12xCSL promoter ([@bib19]) and by in situ hybridization ([Figures S2](#app2){ref-type="sec"}F--S2H). The antibody recognized a band of expected size in western blots ([Figure S2](#app2){ref-type="sec"}I). Consistently, the epitope region against which the antibody was raised is highly conserved across species ([Figures S2](#app2){ref-type="sec"}J and S2K). We found a marked unequal distribution of Notch1 expression among the GFAP^+^ ependymoglia cells in the hot spots ([Figure 2](#fig2){ref-type="fig"}G). Of GFAP^+^ cells, 77% ± 2% were Notch1^+^, whereas 23% ± 2% were Notch1^−^ ([Figure 2](#fig2){ref-type="fig"}H). In addition, the majority of GFAP^+^ cells were either Notch1^+^/GS^+^ or Notch1^−^/GS^−^ ([Figure 2](#fig2){ref-type="fig"}H). This is consistent with type-1 cells being GFAP^+^/GS^+^/Notch1^+^ and type-2 cells being GFAP^+^/GS^−^/Notch1^−^.

We next analyzed the proliferation pattern among the Notch1^+^ ependymoglia cells. We found that the vast majority (94% ± 1%) of proliferating ependymoglia cells in the hot spots were devoid of Notch1 expression ([Figures 2](#fig2){ref-type="fig"}I and 2J), whereas most of the proliferating ependymoglia cells in the non-hot spots were Notch1^+^ ([Figures 2](#fig2){ref-type="fig"}K and 2L). This is in accordance with the observation that most proliferating ependymoglia cells in the hot spots were devoid of GS expression, whereas proliferating ependymoglia cells in the non-hot spots expressed GS ([Figures 2](#fig2){ref-type="fig"}D and 2F).

In close proximity of the proliferation hot spots, we found GFAP^−^ cells away from the ventricle, which expressed the cell-adhesion molecule polysialylated neuronal cell adhesion molecule (PSA-NCAM), a marker for immature neurons ([@bib36]), and which were proliferating as assayed by minichromosome maintenance protein 2 (MCM2) expression ([Figures 2](#fig2){ref-type="fig"}M and 2N). On average, we found 211 ± 44 MCM2^+^/ PSA-NCAM^+^ cells in hot spots. In contrast, regions around the dispersed proliferating type-1 cells were devoid of proliferating type-2 and PSA-NCAM-expressing cells (data not shown). These observations further corroborated the view that the proliferation hot spots are constitutively active neurogenic regions, composed by type-1 and type-2 cells and by neuroblasts, whereas the non-hot spots are essentially devoid of type-2 cells and neuroblasts.

Type-1 Ependymoglia Cells Have Stem Cell Properties {#sec2.3}
---------------------------------------------------

The selective localization of type-2 cells to the proliferating hot spots led us to hypothesize that type-2 cells have stem cell properties. Unexpectedly, our data showed the opposite, indicating that a majority of stem cells are type-1 cells. Long-term label retention in pulse-chase experiments using nucleotide analogs is a distinctive feature of stem cells. We pulsed animals for 3 days with the nucleotide analog bromodeoxyuridine (BrdU) and subsequently chased the analog before sacrificing the animals at various time points. Following a chase period of 3 days, we found 22% ± 3% of BrdU being in type-1 cells. This percentage increased gradually and reached 63% ± 13% after 90 days ([Figures 3](#fig3){ref-type="fig"}A--3C and [S3](#app2){ref-type="sec"}A).The remaining BrdU label was found in GFAP^−^ nonventricular cells after 90 days (data not shown). In addition, type-2 cells in hot spots showed the opposite trend of label retention, with hardly any BrdU found after 90 days ([Figure 3](#fig3){ref-type="fig"}B).

As an additional tool, we treated animals with AraC, which kills proliferating cells. AraC treatment is an established method to selectively eliminate transit-amplifying cells, which divide more frequently than slowly dividing stem cells ([@bib14]). Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) staining shows that AraC causes the death of ventricular GFAP^+^ cells ([Figure S3](#app2){ref-type="sec"}B). In accordance with the label-retention experiment, administration of AraC led to the elimination of type-2 cells, as assayed by Notch1/GFAP/PCNA triple labeling ([Figures 3](#fig3){ref-type="fig"}D and 3F). Twelve hours after AraC injection, the number of type-2 cells was reduced by 86% ± 2% and their number increased by 2.5-fold after a 14 days recovery period following the AraC treatment ([Figures 3](#fig3){ref-type="fig"}E and 3F). Consistently, the number of proliferating type-2 cells increased 3-fold during recovery ([Figures 3](#fig3){ref-type="fig"}E and 3G), indicating the compensatory proliferative burst after the elimination of the type-2 cells. In contrast, neither the total number nor the number of proliferating type-1 cells changed significantly after AraC treatment and during the recovery period ([Figures 3](#fig3){ref-type="fig"}D--3H).

These data show that type-1 ependymoglia cells that make up 92% ± 4% of the ventricle wall of the telencephalon ([Figures S2](#app2){ref-type="sec"}C--S2E) have stem cell properties and suggest that type-2 cells in the hot spots have properties of transit-amplifying cells.

Ependymoglia Cell Dynamics during Neuronal Regeneration {#sec2.4}
-------------------------------------------------------

Next, we tested how ependymoglia cells respond to the ablation of neurons. We tested two possibilities. The first possibility was that only the hot spots respond by increased proliferation of type-1 and type-2 cells and neuroblasts. The second possibility was that both the hot spots and the non-hot spots respond to loss of neurons. To distinguish between these two possibilities, we ablated cholinergic neurons and analyzed hot spots and non-hot spots, which are localized in proximity to the ablated neuronal population ([Figure S4](#app2){ref-type="sec"}). Injection of the selective neurotoxin AF64A led to the ablation and subsequent regeneration of choline acetyltransferase (ChAT)-expressing neurons ([Figures 4](#fig4){ref-type="fig"}A and 4B). During the course of regeneration of cholinergic neurons, we observed an increase of both type-1 and type-2 cells ([Figures 4](#fig4){ref-type="fig"}C--4H). The most striking change that we found was the appearance of type-2 and proliferating PSA-NCAM^+^ cells in and around the non-hot spots ([Figures 4](#fig4){ref-type="fig"}F--4H and 4L--4N). These data indicated the de novo generation of a neurogenic niche as a response to neuronal ablation.

Ependymoglia Cell Dynamics and Notch Signaling during Homeostasis and Neuronal Regeneration {#sec2.5}
-------------------------------------------------------------------------------------------

Next, we tested how manipulation of Notch signaling impinges on ependymoglia cell dynamics during normal homeostasis and after ablation of neurons. To interfere with Notch signaling, we used the small molecule, DAPT, which is a γ-secretase inhibitor ([@bib17]). In the absence of neuronal ablation, DAPT treatment led to increased proliferation of type-2 cells in the hot spots ([Figures 5](#fig5){ref-type="fig"}A--5C). On the other hand, we did not observe any statistically significant change in the proliferation of type-1 cells---neither in the hot spots nor in the non-hot spots ([Figures 5](#fig5){ref-type="fig"}B--5D). We also determined how DAPT treatment influenced the number of proliferating PSA-NCAM^+^ cells and found that it was increased by 45% ± 7% ([Figures 5](#fig5){ref-type="fig"}E--5G).

After ablation of cholinergic neurons, the injury-responsive increased proliferation of type-1, type-2, and PSA-NCAM^+^ cells in the hot spots was not significantly altered by DAPT treatment ([Figures 6](#fig6){ref-type="fig"}A and 6B). Conversely, whereas normal proliferation was not influenced in the non-hot spots by DAPT treatment, the ablation-responsive increase in type-1 cells was inhibited by DAPT ([Figure 6](#fig6){ref-type="fig"}C). Counting the PSA-NCAM^+^ cells in the non-hot spots showed increased proliferation after DAPT treatment ([Figure 6](#fig6){ref-type="fig"}D).

In order to corroborate this interpretation, we analyzed neurosphere cultures. We reasoned that the neurosphere cultures mimic an injury response due to the dissociation process and would primarily be composed by type-1 cells derived from non-hot spots, as these are the quantitatively dominating population (81% ± 3%) in the forebrain. In agreement with the in vivo results, we found that DAPT treatment decreased the proliferation of the neurosphere-forming ependymoglia cells as assayed by EdU incorporation ([Figures 6](#fig6){ref-type="fig"}E--6G).

These results indicated that, during normal homeostasis, stem cell (type-1) proliferation is not Notch-signaling sensitive and proliferation of transit-amplifying cells (type-2) and neuroblasts (PSA-NCAM^+^) is Notch-signaling sensitive. The insensitivity of stem cells to Notch signaling remains in the hot spots also during regeneration; however, the injury-responsive increased stem cell proliferation in the non-hot spots is dependent on Notch signaling.

Discussion {#sec3}
==========

In this paper, we characterized cellular heterogeneity among ventricular radial glia-like ependymoglia cells in the newt telencephalon. Our findings reveal two principal subpopulations among these cells: one having stem cell features (type-1) and the other with features of transit-amplifying cells (type-2; summarized in [Figure 7](#fig7){ref-type="fig"}). We also define differential sensitivity among ependymoglia cells to treatment with the γ-secretase inhibitor DAPT during homeostatic and regenerative conditions, suggesting that Notch signaling has a context-dependent and cell-type-specific role in regulating precursor cell fate in the newt telencephalon (summarized in [Figure 7](#fig7){ref-type="fig"}).

The newt telencephalon harbors distinct proliferation hot spots ([@bib8]). An unexpected observation presented in this paper is that the seemingly randomly proliferating type-1 ependymoglia cells are label-retaining and insensitive to AraC treatment. Hence, the ventricular system in the newt telencephalon appears to be lined by rarely self-renewing stem-like ependymoglia cells, and this may be one factor behind these animals' marked neuroregenerative capacity.

Indeed, upon ablation of cholinergic neurons, we found several indications for the formation of neurogenic niches in non-hot spots. Although, due to the lack of selective tracing methods, the fate of non-hot spot cells in relation to cells generated in the hot spots can at present not be determined, our observations suggest a de novo generation of a lineage in non-hot spots as a response to injury. First, we observed the increased number of proliferating type-1 cells. Second, we observed the appearance of proliferating type-2 cells in vicinity of the type-1 cells. Third, in proximity to the type-1 and newly formed type-2 cells, we also noted an injury-specific appearance of proliferating PSA-NCAM-expressing cells.

The newt brain lacks GFAP-expressing parenchymal astrocytes ([@bib9; @bib33]). It is likely that ependymoglia cells are responsible for functions that are carried out by astrocytes in mammals, such as protecting neurons from excitotoxicity by metabolic regulation of glutamate involving GS ([@bib32]). Whereas many glial markers, for example GFAP and GLAST, are common for all ependymoglia cells in the newt brain, GS selectively labels the type-1 cells. This finding is noteworthy in an evolutionary comparative context. Because GS does not mark cell populations with transit-amplifying characters, this observation may support the view of astrocytes being NSCs in vertebrates ([@bib26]).

It is interesting to note that the zebrafish telencephalon, which is also highly regenerative ([@bib7; @bib27]), lacks a distinct GS^−^ cell population that expresses other canonical glial genes, such as S100β and GFAP ([@bib16; @bib30]). However, the fish telencephalon seems to harbor label-retaining cells with low or no glial marker expression ([@bib16]). Another interesting comparison with the zebrafish telencephalon is that Notch1 is mainly expressed in quiescent radial glia cells in the fish ([@bib13]). In contrast, in the newt telencephalon, the Notch1 antibody equally labels proliferating and nonproliferating cells in the non-hot spots. In addition, no increase in proliferating PSA-NCAM^+^ cells was observed after stab injury to the zebrafish telencephalon ([@bib7]). These observations reflect differences in the cellular organization and the injury response comparing newts and zebrafish. Nevertheless, DAPT treatment has been shown to reduce the injury-induced production of cells with active neurogenin reporter in the zebrafish telencephalon ([@bib24]), which is similar to our findings in the newt telencephalon showing that DAPT treatment reduces the injury-induced proliferation of type-1 cells in the non-hot spots. The altered sensitivity to DAPT treatment of the type-1 cells after injury comparing hot spots and non-hot spots further reinforces the differences between injury-induced and constitutive neurogenesis, as previously suggested by [@bib8] and [@bib25].

The importance of Notch signaling in the regulation of neuronal precursor cell fate has been well documented also in mammals, and perturbation of Notch signaling has profound effects both during homeostatic conditions as well as in injury models ([@bib2; @bib6; @bib11; @bib13; @bib15; @bib20]). In the mouse brain, quiescent NSCs are insensitive to the loss of Notch signaling. However, upon injury-induced activation of NSCs, Notch signaling is required to fully reinstate neurogenesis ([@bib6]). Further cross-species comparisons, preferentially by involving targeted fate-mapping approaches, of how Notch signaling impinges on neurogenesis are likely to reveal novel ways of enhancing regeneration in the adult vertebrate brain.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

Adult red-spotted newt *Notophthalmus viridescens* (Charles Sullivan) were housed at 15°C--20°C. All experimental procedures were performed according to European and local ethical permits.

Treatments {#sec4.2}
----------

BrdU (Sigma) 20 mg/kg was injected intraperitoneally twice daily for 3 days and chased for various amounts of time. Cholinergic ablations were carried out according to [@bib9] by intracranial injection into the lateral ventricle of 50 ng AF64A. ChAT^+^ cells were quantified in the bed nucleus of the stria terminalis. The Notch-signaling reporter 12xCLS-H2BYFP ([@bib19]) was electroporated into the lateral wall of the lateral ventricle as described previously ([@bib8]). AraC (500 mg/kg; Sigma) was delivered via intraperitoneal injections twice daily for 5 days. Animals were either sacrificed 12 hr after the last injection or allowed to recover for 14 days before being scarified. DAPT (N-\[N-(3,5-difluorophenacetyl-L-alanyl)\]- S-phenylglycine t-butyl ester; Axxora) was administered as previously described ([@bib13]). Briefly, a stock solution of 10 mM DAPT in DMSO was diluted in swimming water to a final concentration of 100 μM. Control animals were placed in equal concentration of DMSO. Newts were treated for 48 hr. Newts ablated with AF64A were treated with DAPT between 5 and 7 days after toxin injection.

Cell Culture {#sec4.3}
------------

All media were diluted by 33% with water to match the osmolality of the newt cells. Newts were anesthetized with a solution of 0.1% MS-222 (Sigma). The isolated brain was digested in 30 U/ml Papain (Sigma), L15 (Gibco), 40 μg/ml DNase (Roche), and 2 mg/ml ovamucoid (Worthington Biochemical) for 1 hr at room temperature. Next, L15 containing 2 mg/ml ovamucoid and 40 μg/ml DNases was added at a ratio 1:1 and left at room temperature for 5 min. Cells were spun down and resuspended in L15 and triturated with a p1000. Cell suspension was filter through 30 μm cell strainer (Gibco) before being spun down and resuspended in Dulbecco's modified Eagles medium (DMEM)/F12/Glutamax (Gibco), 2% B27 (Gibco), 100 U/ml penicillin-streptomycin (Gibco), 20 ng/ml EGF (Gibco) and 20 ng FGF-2 (Gibco). Cells were plated in uncoated 24-well plates and cultured at 25°C at 2% CO2. Every fourth day, cells were supplemented with fresh growth media. After 14 days, neurospheres were plated out on dish coated with poly-D-lysine (Sigma) and allowed to differentiate in DMEM/F12/Glutamax media with no growth factors. Neurospheres were generated and cultured as described above either in the presence of 10 μM DAPT (Axxora) or vehicle from days 7 to 9. Twenty micromolar EdU (Invitrogen) was added to the medium for 8 hr at day 9; spheres were dissociated and plated on poly-D-lysine-coated plates (Sigma) for immunohistochemistry.

Immunohistochemistry {#sec4.4}
--------------------

Immunohistochemical staining of brain tissue was performed as described previously ([@bib9; @bib23]). Neurospheres were fixed in 4% formaldehyde for 15 min at room temperature and treated with 0.1% Triton X-100 in PBS (Sigma). Cells and 20 μm newt brain coronal sections were incubated at 4°C for 15--18 hr in blocking solution containing either PBS, 4% goat serum (Invitrogen), and 0.1% Triton X-100 or PBS, 0.2% fish skin gelatin (Sigma), 0.2% BSA (Sigma), and 0.2% Triton X-100 with the following primary antibodies: mouse anti-GFAP-CY3 (1:500; Sigma), goat anti-GFP (1:500; Abcam), guinea pig anti-GLAST (1:1,000; Frontier Institute), rabbit anti-Sox2 (1:500; Abcam), rabbit anti-glutamine synthetase (1:500; Millipore), rabbit anti-MCM2 antibody (1:200; Abcam), PSA-NCAM (1:8,000; Millipore), rabbit anti-Notch1 (1:100; Santa Cruz Biotechnology), mouse anti-PCNA (1:500; Chemicon), rat anti-BrdU (1:500; Accurate Chemical and Scientific), and anti-ChAT (1:250; Millipore). For BrdU and PCNA staining, sections and cells were treated with PBS containing 2 M HCL and 0.5% Triton X-100 for 20 min at 37°C. For PSA-NCAM and MCM2 staining, sections were incubated in citrate buffer (10 mM sodium citrate, 0.05% Tween 20 \[pH 6\]) at 37°C for 30 min. After labeling with the primary antibody, sections and cells were washed 3 × 5 min in PBS before the appropriate secondary antibodies (Molecular Probes) were applied in blocking solution for 2 hr at room temperature. Triple labeling of GFAP with two other antibodies required additional 5 min incubation in 4% formaldehyde at room temperature after incubation with the secondary antibodies. This was followed by 1 hr incubation at room temperature with GFAP-CY3 (1:1,000; Sigma) in blocking solution. Sections were mounted in mounting medium containing 1 mg/ml DAPI (Dako). TUNEL was performed post-antibody incubation following the manufacturer's instructions for cryosections (In Situ Cell Death Detection Kits for detection by fluorescent microscopy; Roche). Images for cell counting of tissue sections were captured with LSM-700 using ZEN software (both Zeiss), Angstrom Grid confocal microscope (Leica Microsystems) using velocity software (PerkinElmer), or Axioplan2 using Axiovision software (both Zeiss). In areas of high cell density, confocal z stacks were captured, and for large areas, confocal tile montages were created. Images were manipulated with Volocity (PerkinElmer) or Photoshop (Adobe) using linear adjustments. Cell counts were performed on a region starting with the proliferation hot spot adjacent to the bed nucleus of the stria terminalis to the most caudal part of the telencephalon.

In Situ Hybridization {#sec4.5}
---------------------

A fragment of *Notch1* was amplified from newt adult brain cDNA using the following primers: For: TCT CCG TTT CAA CAG TCT CC; Rev: AAG TTG GTG GCT GGG AGT GT. The fragment was inserted into pCR4 topo cloning vector using TOPO TA cloning kit (Invitrogen). Digoxigenin-labeled probes were synthesized using T7 and Sp6 RNA polymerase kit (Roche). Brains were dissected out and prepared in a similar manner to immunohistochemical procedure (see above), except that ribonuclease (RNase) free reagents were used. Ten micrometer coronal sections were fixed in 4% formaldehyde for 15 min, treated with 0.2 N HCL for 12 min, washed, and then incubated in acetylation buffer (0.1 M trietholamine and 0.25% acetic anhydride) for 10 min. Next, the slides were rinsed in RNase free water and permeabilized with a solution of 1 μg/ml Proteinase K (Roche) and 2 mM CaCl2 for 15 min at 37°C. The slides were incubated in prehybridization buffer (50% deionized form of amide, 5× saline sodium citrate \[SSC\], 5× Denhardt's solution, 250 μg/ml yeast RNA, 500 μg/ml herring sperm single-stranded DNA \[ssDNA\]; Sigma) for 2 hr at room temperature before being incubated in hybridization solution (50 ng probe, 50% deionized form of amide, 5× SSC, 5× Denhardt's solution, 250 μg/ml yeast RNA, 500 μg/ml herring sperm ssDNA) for 16 hr at 60°C. The slides were then washed with 0.2× SSC buffer containing 0.05% tween 20 at 70°C for 3 × 1 hr. Finally, the probes were detected by TSA Plus Fluorescence for in situ hybridization (PerkinElmer) following the manufacturer's instructions.

Western Blot {#sec4.6}
------------

Newt brains were homogenized using downs homogenizer in lysis buffer containing 50 mM Tris (pH 8; Sigma), 150 mM NaCl (Sigma), 10% glycerol (Sigma), 1% NP40 (Sigma), 0.5% deoxycholate (Sigma), and proteinase inhibitors mix (Roche). Protein extract was boiled in sample buffer (Invitrogen) and ran on SDS-PAGE gel (Invitrogen) before being transferred onto polyvinylidene fluoride membrane. Membranes were incubated overnight at 4°C with rabbit anti-Notch1 antibody (1:1,000; Santa Cruz Biotechnology) in blocking buffer containing Tris-buffered saline, 5% BSA (Sigma), and 0.1% Triton X-100. Anti-rabbit-horseradish peroxidase (1:10,000; GE Healthcare) in blocking buffer was incubated for 1 hr at room temperature before the membrane was treated with enhanced chemiluminescence following the manufacturer's instructions (GE Healthcare) and imaged using Image Quant LAS 4000 (GE Healthcare).

Alignments {#sec4.7}
----------

Notch1 sequences for *Homo sapiens* (ref: [NP_060087.3](ncbi-geo:NP_060087.3){#intref0010}), *Mus musculus* (ref: [NP_032740.3](ncbi-geo:NP_032740.3){#intref0015}), and *Xenopus laevis* (ref: [NP_001081074.1](ncbi-geo:NP_001081074.1){#intref0020}) were obtained from the National Center for Biotechnology database. Notch1 sequence for *Notophthalmus viridescens* was obtained from an inferred proteome ([@bib1]). Alignment was performed using DNAstar mega align.

Statistical Analyses {#sec4.8}
--------------------

Student's t test was used where p values are indicated. In all figures, *n* represents the number of biological replicates.

Supplemental Information {#app2}
========================
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![Neurosphere-Forming Cells in the Newt Brain\
(A and B) Isolated cells from newt brain cultured in DMEM/F12, FGF-2, and EGF formed small spheres after 4 days (A). These spheres increased in size over time (B).\
(C) GFAP^+^ cells are found in the center of the 14-day-old neurospheres.\
(D and E) Neurospheres cultured for 14 days in DMEM/F12, FGF-2, and EGF contain proliferating GFAP^+^ cells as indicated by PCNA labeling (D, arrows) and incorporate EdU (E, arrows).\
(F--H) Neurospheres plated in poly-D-lysine plates and cultured in differentiation medium for 14 days produce Tuj1^+^ cells with long extensions (F and G). GFAP^+^ cells were also observed away from the neurosphere (F and H).\
The scale bars represent 50 μm.](gr1){#fig1}

![Immunohistochemical Characterization of Ventricular Ependymoglia Cells\
(A) All ependymoglia cells are GFAP^+^; proliferation hot spots such as the dorsal pallium (Dp) and the bed nucleus of the stria terminalis (Bst) are marked as well as the striatum (Str). The drawing of the newt brain indicates the plane of section. Lines with arrows demarcate the borders of the hot spots. Arrows highlight even expression of GFAP in the hot spots.\
(B) Sox2 and GFAP are expressed in all ependymoglia cells. Arrow highlights even expression of Sox2 in proliferating PCNA^+^ cells.\
(C) GS/GFAP/MCM2 staining reveals type-1 and type-2 cells. Arrow points to MCM2^+^/GFAP^+^/GS^−^ (type-2) ependymoglia cells in hot spots. Arrowhead points to the surrounding nonproliferating GFAP^+^/GS^+^ (type-1) ependymoglia cells.\
(D) Quantification of ependymoglia cells in hot spots coexpressing GFAP, GS, and MCM2. Note that most MCM2^+^ ependymoglia cells are type-2 cells (GFAP^+^/GS^−^). n = 5; p \< 0.05.\
(E) GS/GFAP/MCM2 expression in non-hot spot. Arrowhead points to proliferating type-1 cell (GFAP^+^/GS^+^).\
(F) Quantification of ependymoglia cells in non-hot spots coexpressing GFAP, GS, and MCM2. Note that most MCM2^+^ ependymoglia cells are type-1 cells (GFAP^+^/GS^+^). n = 5; p \< 0.05.\
(G) Notch1^−^, type-2 ependymoglia cells (arrow) surrounded by Notch1^+^, type-1 ependymoglia cells (arrowhead). Note the colocalization of GS and Notch1 immunoreactivity.\
(H) Quantification of GFAP-, Notch1-, and GS-expressing ependymoglia cells shows that, in hot spots, the vast majority of GFAP^+^ cells were type-1 (Notch1^+^/GS^+^). n = 4; p \< 0.05.\
(I) The majority of PCNA^+^ cells in hot spots are type-2 ependymoglia cells (GFAP^+^/Notch1^−^; arrow).\
(J) Quantification of ependymoglia cells in hot spot regions coexpressing GFAP, Notch1, and PCNA. Note that almost all PCNA^+^ ependymoglia cells are type-2 cells (GFAP^+^/Notch1^−^). n = 5; p \< 0.05.\
(K and L) Few PCNA^+^ type-1 (GFAP^+^/Notch1^+^) ependymoglia cells were observed outside of hot spots. Quantified in (L). n = 5; p \< 0.05.\
(M) PSA-NCAM (NCAM) and type-2 (GFAP^+^/Notch1^−^) ependymoglia cells in hot spots (arrow). The surrounding region contains type-1 (GFAP^+^/Notch1^+^) ependymoglia cells and is devoid of PSA-NCAM expression (arrowhead).\
(N) MCM2-expressing PSA-NCAM^+^ cells in hot spots (arrow).\
Data represented as mean ± SEM. The scale bars represent 50 μm.](gr2){#fig2}

![Type-1 Cells Are Resistant to AraC and Retain BrdU Labeling after Extended Chase\
(A--C) A pulse of BrdU was chased for 3 days (A). BrdU-labeled type-2 ependymoglia cells in hot spots (arrow). BrdU-labeled type-1 ependymoglia cells after a 90-day chase (arrowhead; B). Type-2 ependymoglia cells were identified by lack of Notch1 expression (arrow). Percentage of GFAP^+^/BrdU^+^ cells that were type-1 ependymoglia cells (C). p \< 0.05 between 3 days chase and 90 days chase. n = 4.\
(D--H) AraC treatment (D) reduces the number of type-2 ependymoglia cells (arrow) but had no effect on type-1 ependymoglia cells in hot spots. After 14 days of recovery (E), the number of type-2 ependymoglia cells increased (F). p \< 0.05 between control and AraC treatment. n = 5. Recovery for 14 days after AraC treatment also caused an increase in PCNA^+^ type-2 ependymoglia cells but had no effect on the proliferation of type-1 ependymoglia cells (G). p \< 0.05; n = 5. The number of PCNA^+^ type-1 cells was also unaffected in non-hot spots (H). n = 5.\
Data represented as mean ± SEM. The scale bars represent 50 μm.](gr3){#fig3}

![Ablation of ChAT^+^ Neurons Leads to De Novo Generation of Type-2 and Proliferating PSA-NCAM Cells in Non-Hot Spots.\
(A and B) ChAT^+^ neurons are present in the parenchyma of the bed nucleus of the stria terminalis (A). The drawing of the newt brain indicates the plane of section. ChAT^+^ neurons are lost 7 days after injection of AF64A (A) and subsequently regenerate after 25 days (A). Quantified in (B). p \< 0.05; n = 5.\
(C--E) Compared to control (C), there is an increase of PCNA^+^ type-2 ependymoglia cells (arrow) in the hot spot adjacent to the ablated ChAT^+^ neurons (D). Quantified in (E). p \< 0.05; n = 5.\
(F--H) Compared to control (F), ablation of ChAT^+^ neurons caused an increase of PCNA^+^ type-1 and the appearance of PCNA^+^ type-2 ependymoglia cells (arrow) in the ventral non-hot spot. Quantified in (H). p \< 0.05; n = 5.\
(I--K) Compared to control (I), ablation of ChAT^+^ neurons caused an increase of PSA-NCAM (NCAM) MCM2^+^ cells in the hot spot (arrow). Quantified in (K). p \< 0.05; n = 5.\
(L--N) Lack of PSA-NCAM^+^/MCM2^+^ cells in the ventral non-hot spot (L). Ablation of ChAT^+^ neurons caused the appearance of PSA-NCAM^+^/MCM2^+^ cells in non-hot spots (arrow; M). Quantified in (N). p \< 0.05; n = 5.\
Data represented as mean ± SEM. The scale bars represent 50 μm.](gr4){#fig4}

![Inhibition of Notch Signaling Causes an Increase in Cell Proliferation during Homeostatic Conditions\
(A--D) Control (A) versus DAPT-treated (B) brains shows an increase in PCNA^+^ type-2 ependymoglia cells in hot spots (arrows). Quantified in (C). p \< 0.05; n = 5. No significant effect of DAPT treatment on non-hot spot cells (D). n = 5.\
(E--G) Control (E) versus DAPT-treated (F) brains shows an increase in MCM2^+^ PSA NCAM^+^ (NCAM) cells (arrows) in hot spots. Quantified in (G). p \< 0.05; n = 4.\
Data represented as mean ± SEM. The scale bars represent 50 μm.](gr5){#fig5}

![Injury Leads to Changes in the Cellular Response to Inhibition of Notch Signaling\
(A and B) After ablation of cholinergic neurons, DAPT treatment does not significantly affect the injury-induced proliferation neither of type-1 and type-2 ependymoglia cells (A) nor the PSA NCAM^+^ (NCAM) cells (B) in hot spots. n = 5.\
(C and D) After ablation of cholinergic neurons, DAPT treatment leads to a decrease in injury-induced proliferation of type-1 ependymoglia (C) and an increase in PSA-NCAM^+^ cells in non-hot spots. p \< 0.05; n = 5.\
(E--G) DAPT treatment caused a decrease in the incorporation of EdU by GFAP^+^ neurosphere cells (E and F). Quantified in (G). p \< 0.05; n = 4.\
Data represented as mean ± SEM. The scale bars represent 50 μm.](gr6){#fig6}

![Summary of Proliferation Dynamics during Homeostasis and Regeneration in the Presence or Absence of Notch-Signaling Inhibitor\
(A) Expression patterns of various glial and proliferation markers expressed by type-1 and type-2 ependymoglia cells.\
(B) In the graphic representation of the cells lining the ventricle, squares represent type-1 cells (GFAP^+^, Notch1^+^, and GS^+^), diamonds depict type-2 cells (GFAP^+^, Notch1^−^, and GS^−^), and circles denote PSA-NCAM^+^ neuroblasts. The thickness of the arrows indicates the relative number of cycling cells, with dashed line being the lowest and thick bold being the highest.](gr7){#fig7}
